- ISIN
- US7574681034
- CUSIP
- 757468103
- Sector
- Healthcare
- IPO Date
- Jan 7, 2013
Highlights
- EPS (TTM)
- -$5.17
- Total Revenue (TTM)
- $9.55M
- Gross Profit (TTM)
- $6.16M
- EBITDA (TTM)
- -$7.91M
- Year Range
- $0.71 - $3.31
- ROA (TTM)
- -36.74%
- ROE (TTM)
- -218.21%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RDHL Performance Chart
RedHill Biopharma Ltd. (RDHL) is down 18.5% since the beginning of the year. At $1 per share, RDHL is trading 74.6% below its 52-week high of $3. Investors who bought $1,000 worth of RDHL shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Returns By Period
RedHill Biopharma Ltd. (RDHL) has returned -18.45% so far this year and -55.79% over the past 12 months. Over the last ten years, RDHL has returned -61.10% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
RedHill Biopharma Ltd.
- 1D
- 3.22%
- 1M
- -14.27%
- YTD
- -18.45%
- 6M
- -26.96%
- 1Y
- -55.79%
- 3Y*
- -72.96%
- 5Y*
- -83.57%
- 10Y*
- -61.10%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
RDHL Monthly Returns History
Based on dividend-adjusted daily data since Jan 7, 2013, RDHL's average daily return is -0.10%, while the average monthly return is -1.67%.
Historically, 43% of months were positive and 57% were negative. The best month was Nov 2023 with a return of +348.9%, while the worst month was Dec 2022 at -61.0%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, RDHL closed higher 44% of trading days. The best single day was Nov 27, 2023 with a return of +217.0%, while the worst single day was Jan 25, 2024 at -39.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.45% | -20.49% | -23.18% | 46.27% | -8.26% | -16.00% | -18.45% | ||||||
| 2025 | -4.84% | -43.65% | -20.12% | -17.11% | -18.82% | 8.38% | -32.47% | 3.05% | 60.74% | -40.09% | -7.69% | -14.17% | -83.41% |
| 2024 | -60.27% | 6.21% | -13.98% | -18.61% | 6.21% | -19.08% | 3.61% | -11.48% | 2.83% | -5.73% | 3.16% | -26.94% | -82.99% |
| 2023 | 55.38% | 3.90% | -54.86% | -40.59% | -4.53% | -48.28% | 6.67% | -31.41% | -41.91% | -12.65% | 348.93% | -27.00% | -73.98% |
| 2022 | 1.94% | -16.73% | 15.07% | -32.94% | -33.73% | -22.32% | 0.00% | 3.37% | -44.12% | 38.49% | -48.27% | -61.03% | -94.56% |
| 2021 | 4.21% | 12.83% | -22.95% | -6.83% | 6.30% | -5.10% | -6.40% | 56.83% | -54.65% | 18.78% | -46.32% | -11.64% | -68.07% |
Benchmark Metrics
RedHill Biopharma Ltd. has an annualized alpha of -30.46%, beta of 0.90, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since January 07, 2013.
- This stock participated in 243.21% of S&P 500 Index downside but only -29.23% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -30.46%
- Beta
- 0.90
- R²
- 0.02
- Upside Capture
- -29.23%
- Downside Capture
- 243.21%
Return for Risk
Risk / Return Rank
RDHL ranks 18 for risk / return — in the bottom 18% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for RedHill Biopharma Ltd. (RDHL) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RDHL | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.59 | ||
| Sortino ratioReturn per unit of downside risk | -3.28 | ||
| Omega ratioGain probability vs. loss probability | 0.94 | 1.37 | -0.43 |
| Calmar ratioReturn relative to maximum drawdown | -0.79 | 2.78 | -3.58 |
| Martin ratioReturn relative to average drawdown | -1.09 | 12.44 | -13.53 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the RedHill Biopharma Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the RedHill Biopharma Ltd. was 100.00%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current RedHill Biopharma Ltd. drawdown is 100.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -100.00%Mar 2026 | 10y 9mo | — | 11y 9dJun 2015 - now |
2014 bear market2014 | -58.18%Nov 2014 | 5mo 7d | 7mo 1d | 1y 3dJun 2014 - Jun 2015 |
2013 bear market2013 | -38.90%Jul 2013 | 5mo 7d | 6mo 11d | 11mo 18dFeb 2013 - Jan 2014 |
2014 pullback2014 | -8.79%Jan 2014 | 10d | 27d | 1mo 7dJan 2014 - Feb 2014 |
2014 pullback2014 | -5.91%Apr 2014 | 13d | 27d | 1mo 10dApr 2014 - May 2014 |
Drawdown Indicators
| RDHL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -70.45% | -9.10% | -61.35% |
Max Drawdown (3Y)Largest decline over 3 years | -98.97% | -18.90% | -80.07% |
Max Drawdown (5Y)Largest decline over 5 years | -99.99% | -25.43% | -74.56% |
Max Drawdown (10Y)Largest decline over 10 years | -100.00% | -33.92% | -66.08% |
Current DrawdownCurrent decline from peak | -100.00% | -1.80% | -98.20% |
Average DrawdownAverage peak-to-trough decline | -63.90% | -10.71% | -53.19% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 51.33% | 2.03% | +49.30% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of RedHill Biopharma Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how RedHill Biopharma Ltd. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for RDHL relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, RDHL has a P/S ratio of 0.2. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RDHL
Add RedHill Biopharma Ltd. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RDHL